AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Mural Oncology announces the effectiveness of its scheme of arrangement and completion of acquisition by XRA 5 Corp, a subsidiary of XOMA Royalty Corporation. The scheme, which acquired the entire issued and to be issued share capital of Mural, became effective on December 5, 2025. Distribution of cheques and crediting of DTC participant accounts for the cash consideration is expected to commence shortly.
Daily stocks & crypto headlines, free to your inbox
Comments
No comments yet